# PAVO (NCT05169437)

> Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05169437
- Phase: PHASE2
- Status: TERMINATED
- Sponsor: Tempus AI
- Conditions: Solid Tumor; Breast Tumor; Colon Tumor, Malignant; Lung Tumor; Urologic Cancer; Pancreatic Cancer; Melanoma; Metastatic Cancer; Locally Advanced Solid Tumor; Esophageal Cancer; Endometrial Cancer; Head and Neck Cancer
- Interventions: Niraparib
- Enrollment: 22
- Primary outcome: Overall Response Rate (ORR) - Independent Central Review (ICR)

## Commentary we found

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=pavo-nct05169437